![](/sites/default/files/2022-08/IMMUNO-ONCOLOGY-img.jpg)
Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.
Asia Pacific has shown significant increase in Immuno-oncology trials between 2017 and 2021 and contributes to more than a third of the global clinical development of Immune-oncology drugs.